



1634

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

In Re the Application of:

GUIDA et al.

Serial No.: 10/085,612

Filed: February 26, 2002

Atty. File No.: 4389-5-C1

For: "METHODS FOR EVALUATING THE
ABILITY TO METABOLIZE
PHARMACEUTICALS AND
COMPOSITIONS THEREFOR"

Group Art Unit: 1634

Examiner:

INFORMATION DISCLOSURE
STATEMENT

| |
|---|
| <p>CERTIFICATE OF MAILING</p> <p>I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 ON <u>4/26/02</u>.</p> <p>SHERIDAN ROSS P.C.</p> <p>BY: <u>Christine Jacquet</u></p> |
|---|

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby provides a copy of each of the documents identified on the enclosed PTO Form 1449, although Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: ROBERT D. TRAVEL
Robert D. Traver
Registration No. 47,999
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: 26 April 2002



RECEIVED

MAY 03 2002

TECH CENTER 1600/2900¹ OF 3

| | | |
|--|----------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | ATTY. DOCKET NO. 4389-5-C1 | SERIAL NO. 10/085,612 |
| | APPLICANT GUIDA et al. | |
| | FILING DATE February 26, 2002 | GROUP ART 1634 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROP. |
|----------------------|----|--------------------|---------|----------------|-------|--------------|---------------------------|
| | AA | 6,174,684 | 1/16/01 | Rebbeck et al. | 435 | 6 | 8/11/99 |
| | AB | 6,183,963 | 2/6/01 | Sinnett et al. | 435 | 6 | 10/23/98 |
| | | | | | | | |


FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION | |
|--|----|--------------------|---------|---------|-------|--------------|-------------|----|
| | | | | | | | YES | NO |
| | AC | WO 93/18178 | 9/16/93 | PCT | | | | |
| | AD | WO 00/39332 | 7/6/00 | PCT | | | | |
| | | | | | | | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|--|
| AE | Aoyama et al., <i>The Journal of Biological Chemistry</i> , 264(18): 10388-10395 (1989). |
| AF | Aoyama et al., GenBank Accession No. J04813 (1993). |
| AG | Aoyama et al., GenBank Accession No. NM000777 (2000). |
| AH | Ball et al., <i>Clinical Pharmacology & Therapeutics</i> , 66(3): 288-294 (1999). |
| AI | Bork et al., <i>The Journal of Biological Chemistry</i> , 264(2): 910-919 (1989). |
| AJ | Brockmoller et al., <i>Toxicol Lett</i> , 102-103:173-83 (1998). |
| AK | Domanski et al., <i>Molecular Pharmacology</i> , 59:386-392 (2001). |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



SHEET 2 OF 3

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
4389-5-C1SERIAL NO.
10/085,612INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT
GUIDA et al.FILING DATE
February 26, 2002GROUP ART
163

RECEIVED

MAY 03 2002


TECH CENTER 1600/2900

| | |
|----|---|
| AL | Dunning et al., <i>Cancer Epidemiology, Biomarkers & Prevention</i> , 8: 843-854 (1999). |
| AM | Finta et al., <i>GENE</i> , 260: 13-23 (2000). |
| AN | Fryer et al., <i>IARC Sci Publ</i> , 148: 303-322 (1999). |
| AO | Gellner et al., GenBank Accession No. AF280107 (2000). |
| AP | Gonzalez et al., <i>DNA</i> , 7(2): 79-86 (1988). |
| AQ | Gonzalez et al., GenBank Accession No. P08684 (1988). |
| AR | Hashimoto et al., <i>Eur. J. Biochem.</i> , 218: 585-595 (1993). |
| AS | Hashimoto et al., GenBank Accession No. D11131 (2000). |
| AT | Helzlsouer et al., <i>Journal of the National Cancer Institute</i> , 90: 512-518 (1998). |
| AU | Hengstler et al., <i>Recent Results Cancer Res.</i> , 154: 47-85 (1998). |
| AV | Hilbert et al., <i>The Journal of Biological Chemistry</i> , 272(10): 6733-6740 (1997). / |
| AW | Hsieh et al., GenBank Accession No. AF209389 (1999). |
| AX | Jounaidi, Y., GenBank Accession No. X90579 (1996). |
| AY | Jounaidi et al., <i>Biochemical and Biophysical Research Communications</i> , 205(3): 1741-1747 (1994). x |
| AZ | NCBI Annotation Project, GenBank Accession No. XM_011598 (2001). |
| BA | Peyronneau et al., <i>Eur. J. Biochem</i> , 218: 355-361 (1993). |
| BB | Sachse et al., <i>Am. J. Hum. Genet.</i> , 60: 284-295 (1997). |
| BC | Schuetz et al., <i>Archives of Biochemistry and Biophysics</i> , 274(2): 355-365 (1989). |
| BD | Schuetz, GenBank Accession No. L26985 (1994). |
| BE | Schuetz et al., GenBank Accession No. L35912 (1996). |
| BF | Sherif et al., <i>Cancer Letters</i> , 107: 229-233 (1996). |
| BG | Shi-jie et al., <i>The Journal of Biological Chemistry</i> , 273(6): 3517-3527 (1998). |
| BH | Skolnick, <i>J. Am. Med. Assn.</i> , 275(8): 581-2 (1996). |
| BI | Strange et al., <i>IARC Sci. Publ.</i> , 148: 231-249 (1999). |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 OF 3

| | | |
|--|----------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | ATTY. DOCKET NO. 4389-5-C1 | SERIAL NO. 10/085,612 |
| | APPLICANT GUIDA et al. | |
| | FILING DATE February 26, 2002 | GROUP ART 1634 |

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

| | | |
|--|-----|--|
| | BJ' | Strange et al., <i>Chem. Biol. Interact</i> , 24 (111-112): 351-364 (1998). |
| | BK | Sulston et al., GenBank Accession No. AC005020 (2000). |
| | BL | Watanabe, M., <i>Toxicol. Lett</i> , 28 (102-103): 167-171 (1998). |
| | BM | Westlind et al., <i>Biochemical and Biophysical Research Communications</i> , 259 : 201-205 (1999). |
| | | |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |